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Abstract
Background: Africa is considered an area of high endemicity for hepatitis A virus infection. However, in the past
two decades, tremendous progress has been made in improving water sources and sanitation which are risk factors
for hepatitis A virus infection. Recent studies suggest that several African countries could be in epidemiological
transitions due to the evident socio-economic development. As a result, there may be a decrease in the exposure
to and infection with hepatitis A virus at an early age. Understanding and mapping the shifting epidemiology is
vital in developing control measures against the disease. We are conducting a comprehensive systematic review
study to document the current burden of hepatitis A virus infection in Africa.
Methods: Our population of interest is children between 1 and 10 years in any African country. We will select
cross-sectional, case-control, and cohort studies that have tested hepatitis A virus infection by serological confirmation
of antibodies against the virus. We will search for eligible studies published without language restrictions from PubMed,
Scopus, Africa-wide, Web of Science, and WHOLIS as well as the reference lists of the relevant articles. Two
authors will independently review the search outputs, select eligible articles, and extract pre-defined study
outcomes. Inconsistencies will be resolved by discussion and consensus among the authors.
Data will be extracted using a standardised data collection form. Trends in the prevalence and/or incidence will
be evaluated by urban and rural setting if sufficient data is available. Where there is sufficient homogeneity
between studies, meta-analysis will also be conducted, otherwise the results will be presented in a narrative
format.
Discussion: The systematic review will generate up-to-date information on the current burden of hepatitis A
virus in Africa. This information may have implications on policy for hepatitis A vaccination on individual African
countries.
Systematic review registration: CRD42015023764
Background
Hepatitis A is a common viral infection that is associ-
ated with poor access to the following: safe and clean
drinking water, sanitation, and hygiene [1–3]. Globally,
1.4 million cases of hepatitis A virus (HAV) occur annu-
ally with a majority of the cases concentrated in the less
developed countries where the risk factors facilitate
transmission [3]. In the past two decades, the HAV cases
have declined dramatically in many parts of the world
due to improved socio-economic developments and
partly due to the availability of vaccines against the virus
[2, 4, 5]. The advances in hygiene and sanitation have re-
sulted to an increased age at which children get first ex-
posure to or infection with HAV. In order to develop
and improve the strategies for HAV infection control, it
is important to constantly assess the epidemiology of the
disease. Hence, we are conducting this review to evalu-
ate the burden of HAV infection in Africa.
A systematic review on HAV infection burden in the
world by the World Health Organisation (WHO), con-
ducted in 2009, showed that infection rates remain high in
most African countries [3]. Africa is thus still considered a
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continent of high HAV endemicity, with most of the
population infected during early childhood, an age at
which the infection is characterised by asymptomatic ill-
ness [3, 4]. Infection with HAV during early childhood re-
sults to a majority of the population acquiring lifelong
immunity to the disease. It is not necessary to have rou-
tine immunisation programmes against HAV in high-
endemic settings. In contrast, low and intermediate HAV
endemic countries have a majority of children who do not
get exposed during early childhood which can result into a
large population of susceptible adolescents and adults later
in life. In these settings, routine immunisation against
HAV is recommended [3].
Given that the hepatitis A disease severity is associ-
ated with age, there is a risk of outbreaks and other
economic implications on the community and the
health system if HAV infection occurs later, after the
childhood period [3, 6].
The 2009 systematic review by WHO showed the infec-
tion rates for HAV to be high in Africa [3]. However, re-
cent studies suggest a general decline in HAV infection in
some countries [4, 7]. In Africa, urban areas are transition-
ing to low rates of HAV infection while high rates of infec-
tion are still prevalent in rural areas, particularly among
low social economic classes [2, 6, 8. A 2008 study in Egypt
confirmed the HAV infection decline in children from low
social class having 81 % prevalence compared to those of
high class with a prevalence rate of 27.3 % [1]. This change
in HAV endemicity could be attributed to socio-economic
development that has occurred in the last decade [3]. Un-
derstanding and mapping the shifting disease epidemi-
ology from childhood to adulthood is important for the
development and review of hepatitis A vaccine policies in
Africa.
In Latin America, evidence of epidemiological transi-
tion of HAV infection has been used to influence vac-
cine policy change [9, 10]. Argentina, as an example,
introduced a single-dose universal vaccination against
HAV infection in 2005 in response to evidence of shift-
ing epidemiology from high endemic to medium en-
demic [11]. Brazil and Chile who have confirmed similar
epidemiological trends to Argentina are evaluating the
possibility of introducing targeted vaccination programs
[5, 12]. These examples show the need to understand
the current HAV epidemiology in order to design na-
tional specific control strategies.
Rationale
The possible shift in HAV epidemiology characterised by
most infection occurring late in childhood and adult-
hood is not well understood in Africa. The change in
HAV endemicity in African countries will have vaccine
policy implications towards the control of HAV. Cur-
rently, most Expanded Programme on Immunisation
(EPI) on the continent do not include the hepatitis A vac-
cine in the routine schedule, under the presumption that
immunity is acquired early in life [3, 4]. While infection in
early life is asymptomatic, the disease severity increases
with age. As such, an investigation of the possible shift in
HAV epidemiology, particularly in childhood is important
to inform policy on HAV control strategies.
An up-to-date profile on the changing epidemiology of
the disease will provide empirical evidence that can
guide policy makers when developing evidence-based
hepatitis A vaccination and prevention strategies in
Africa. Although the systematic review by WHO covered
all countries of the world, studies were only sourced
from a single database (PubMed) and only 23 countries
from Africa were included at the time. We therefore
propose an up-to-date and more comprehensive system-
atic review that will identify all relevant studies pub-
lished on the topic in several databases. Our systematic
review builds on to the review by WHO in 2009 with a
focus on African continent. This study will seek to deter-
mine the current age-related HAV seroprevalence, moni-
tor the trends in the disease burden, and document any
emerging epidemiological changes that have occurred in
the past 10 years. The past 10-year period is charac-
terised by significant continental improvements in sani-
tation and access to clean water.
Objectives
1. Estimate the endemicity of HAV infection among
1–10 years old in different countries in Africa
2. Estimate the age-specific HAV prevalence and/or
incidence in different African countries
3. Evaluate the trend of HAV prevalence and/or




We will select all studies that have a clearly defined preva-
lence and/or incidence rate which is defined as presence
of anti-HAV antibodies by confirmed blood tests within a






The review will include studies involving all children
older than a year and up to 10 years in any African
country. Children under the age of 1 year normally ac-
quire passive immunity (antibodies) from their mothers
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that wanes after 6 months. Therefore, studies with partici-
pants under the age of 1 year will be excluded.
The 10-year cutoff point will be used as this is the
period when substantial improvements in hygiene, water,
and sanitation which are risk factors for HAV infection
have occurred following the adoption of the Millennium
Development Goals (MDGs) and the establishment of
global initiatives targeting water and sanitation improve-
ments1 [13, 14]. As such, studies involving participants
older than 10 years will be excluded.
Inclusion and exclusion criteria for participants
Inclusion criteria
 Persons aged 1 up to 10 years
 All studies with clear serological confirmation of
anti-HAV antibodies by blood tests
 Studies with defined denominator
 Studies must have reported seroprevalence for at
least two different age range within 1–10 years of age.
Exclusion criteria
 Published after May 2015 or before 2005
 Not conducted on African continent
 No defined serological confirmation
 Case reports
 Studies focusing on high-risk groups, people with
human immunodeficiency virus (HIV) or liver disease
Types of interventions
Not applicable.
Types of outcome measures
Primary outcomes
1. Prevalence of HAV.
Prevalence will be defined as presence of anti-HAV
(IgG) antibodies in serologic blood samples taken from
population-based samples.
Secondary Outcomes
1. Age-specific prevalence of HAV
2. Trends in hepatitis A virus prevalence in Africa.
3. Incidence rate of HAV in Africa
Search methods for identification of studies
We will select studies conducted in any African country
where population studies of anti-HAV antibodies were
conducted without language restrictions and with time
limits of between 2005 and 2015. The search strategy
will use both medical subject heading (MeSH) terms and
text words which will be adapted for each database.
Eligible studies will be searched in PubMed, Scopus,
Africa-Wide, Web of Science, and WHOLIS. We will
also search for other relevant articles from the reference
lists of publications. Appendix 1 shows our proposed
search strategy, applied in PubMed database to identify
relevant studies.
Data collection and analysis
Selection of studies
The primary author will screen the search output by first
reading the titles and abstracts, guided by the inclusion
and exclusion criteria described above. Then, the first
and second authors will independently screen the full ar-
ticles of potentially eligible articles to evaluate whether
they meet the inclusion criteria of population, condition,
study setting, and outcomes. Inconsistencies in the list
of eligible studies will be resolved through discussion
and consensus and if need be, the opinion of the other
last two authors will resolve any disagreements.
Data extraction and management
Data will be extracted from the text, tables, and figures
onto a standardised data extraction form (Appendix 2).
In cases of unclear data or uncertainty in eligibility, we
will contact the corresponding authors of the studies se-
lected to get clarification of the unclear information.
The following data points will be extracted from the
studies that meet our eligibility criteria.
 Study characteristics: period, design, objectives, and
inclusion criteria
 Study population: country, setting, and
denominators
 Diagnostic methods: confirmed blood test for anti-
HAV antibodies
 Prevalence or seroprevalence of HAV: confirmed cases
 Incidence rate of HAV
 Patient characteristics: age of the children (mean or
median age as presented in the included studies)
Assessment of risk of bias
The quality of studies included in the review will be
assessed using a scoring scale tool that was adapted from
the Hoy et al. guidelines for evaluating prevalence stud-
ies (Table 1) [15]. A quality sum score will be calculated
from the external and internal validity items in order to
determine eligibility of articles and to assess consistency
between the study authors [16].
Dealing with missing data
For any included studies with missing data, we will con-
tact the corresponding author of the study to provide us
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with the missing data points. In situations where we do
not get the missing data, we will describe the missing
data and examine the extent to which the missing data
may impact the results.
Assessment of heterogeneity
The included studies will be assessed for heterogeneity
using the chi-squared test of homogeneity (significant
for P < 0.1) and quantified using the I-squared statistic
[17]. In instances where there is extensive heterogeneity
between the studies such that statistical pooling is not
feasible, the results will be presented in a narrative format.
Where homogeneity exists between studies (I-squared
statistic <50 %), a Mantel-Haenszel random effects model
will be used to pool data in a meta-analysis. We will
use meta-regression to determine factors systematically
associated with HAV infection. We will include income
status of the countries as classified by World Bank,
urban versus rural settings, and diagnosis criteria in
our meta-regression models.
Assessment of reporting biases
Publication bias will be assessed using funnel plots.
Data synthesis
The results from the studies will be reported as prevalence
and/or incidences summarised by country and the year the
study was conducted. To take into account the between-
study variability, the data will be combined by random ef-
fects analysis using the restricted maximum likelihood esti-
mation method. In addition, a meta-regression will be done
to explore the association between HAV infection preva-
lence and time. A trend analysis using the year the study
was conducted will be done to investigate the time trends
and the infection rates in Africa. STATA software (STATA
Corporation, College Station, TX, USA) will be used to per-
form the statistical calculations on the prevalence and/or
incidences data.
Subgroup analysis
Subgroup analyses will be conducted if possible on the
following: income status of the countries as classified
by World Bank [18, 19], urban versus rural settings,
and diagnosis criteria. In addition, subgroup analysis
will be performed based on the WHO classification
(WHO AFRO versus WHO EMRO) as these regions
have different disease epidemiology profiles. We may
conduct additional analysis based on region, for in-
stance West Africa, Southern Africa, and East Africa, if
we have sufficient data.
Sensitivity analysis
The effect of the sample size will be assessed through
multiple sensitivity analyses which will evaluate the ef-
fect of excluding some studies that did not meet the
study criteria. In addition, we will also conduct a sensi-
tivity analysis to establish if the results are influenced by
methodological differences.
Reporting of the review
The findings in our systematic review will be summarised
in a flow diagram that will outline the selection process as
per PRISMA guidelines for reporting systematic reviews.
This will also include the list of excluded studies and the
reasons for exclusion. In-text descriptions will be used to
describe the qualitative data in the studies.
Discussion
Although it is presumed that the HAV infection is highly
prevalent during early childhood in Africa, the current
epidemiological changes present new challenges for con-
trol of the disease, especially in adults who may have
severe episodes [3, 4]. The growing population of sus-
ceptible adults that evade infection in childhood will re-
sult to an increase in the occurrence of clinical disease
and potential epidemics. It is well established that infec-
tion in adulthood increases the risk of morbidity and
mortality from the disease [3, 6]. With the current strat-
egy of no vaccination, management of clinical illness will
create a significant burden on the fragile health systems
which are coping with HIV/AIDS, tuberculosis, malaria,
Table 1 Quality assessment criteria
Items Quality score
External validity
1. Was the study’s target population a close representation
of the national population in relation to relevant
variables?
(1 point)
2. Was the sampling frame a true or close representation
of the target population?
(1 point)
3. Was some form of random selection used to select
the sample OR was a census undertaken?
(1 point)
4. Was the likelihood of non-response bias minimal? (1 point)
Total (4 points)
Internal validity
1. Were data collected directly from the participants
(as opposed to a proxy)?
(1 point)
2. Was an acceptable case definition used in the study? (1 point)
3. Was the study instrument that measured the parameter
of interest shown to have validity and reliability?
(1 point)
4. Was the same mode of data collection used for all
participants?
(1 point)
5. Was the length of the shortest prevalence period for
the parameter of interest appropriate?
(1 point)
6. Were the numerator(s) and denominator(s) for the
parameter of interest appropriate?
(1 point)
Total (6 points)
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and other infectious diseases. In the long term, this is
not a sustainable approach as the economic cost of
managing HAV infection will be limited due to re-
source constraints in the health sector. The burden of
the disease on individuals and households will also
increase, as infection can lead to losses in productiv-
ity [3, 20]. The economic and individual burden of
HAV infection can be mitigated by vaccination pro-
grams that correspond to the epidemiological pattern
of the disease.
Given that the prevalence of HAV is closely associated
with the level of development, we would expect further
decline in HAV infection in most African countries as they
continue implementing strategies that lead to improve-
ments in water, hygiene, and sanitation as part of the
United Nations post-2015 Sustainable Development Goals
(SDGs) [21]. With the current strategy of no vaccination,
Africa sits on an impending HAV epidemic if epidemi-
ology of the disease is not well understood and appropriate
measures for control adopted. The lack of systematic evi-
dence showing the changing trends limits the adjustment
of current policy on control and development of future pol-
icy on prevention. Therefore, this systematic review is im-
portant to highlight the epidemiological trends of HAV
infection which would inform decision makers on HAV in-
fection control and prevention in African countries.
Endnotes
1The water decade beginning from 2005 to 2015 and
the sustainable sanitation: the drive to 2015 for sanita-
tion launched in 2010 initiative
Appendix 1
Table 2 Search strategy
Query number Search term
#1 hepatitis a[MeSH Terms] OR “hepatitis a”[All Fields]
#2 (((((((“hepatitis a virus”[MeSH Terms] OR “hepatitis a virus”[All Fields]) OR (“hepatitis a”[MeSH Terms] OR “hepatitis a”[All Fields] OR
(“infectious”[All Fields] AND “hepatitis”[All Fields]) OR “infectious hepatitis”[All Fields])) OR ((“virology”[MeSH Terms] OR “virology”[All
Fields] OR “viral”[All Fields]) AND (“hepatitis”[MeSH Terms] OR “hepatitis”[All Fields] OR “hepatitis a”[MeSH Terms] OR “hepatitis a”[All
Fields]))) OR (“hepatitis a virus”[MeSH Terms] OR “hepatitis a virus”[All Fields] OR “hav”[All Fields])) NOT (“hepatitis b”[MeSH Terms] OR
“hepatitis b”[All Fields])) NOT (“hepatitis c”[MeSH Terms] OR “hepatitis c”[All Fields] OR “hepacivirus”[MeSH Terms] OR “hepacivirus”[All
Fields])) NOT (“hepatitis d”[MeSH Terms] OR “hepatitis d”[All Fields])) NOT (“hepatitis e”[MeSH Terms] OR “hepatitis e”[All Fields])
#3 #1 OR #2
#4 ((((“seroepidemiologic studies”[MeSH Terms] OR (“seroepidemiologic”[All Fields] AND “studies”[All Fields]) OR “seroepidemiologic
studies”[All Fields] OR “seroprevalence”[All Fields]) OR (“epidemiology”[Subheading] OR “epidemiology”[All Fields] OR
“epidemiology”[MeSH Terms])) OR (“epidemiology”[Subheading] OR “epidemiology”[All Fields] OR “prevalence”[All Fields] OR
“prevalence”[MeSH Terms])) OR (“epidemiology”[Subheading] OR “epidemiology”[All Fields] OR “incidence”[All Fields] OR
“incidence”[MeSH Terms])) OR burden[All Fields]
#5 #3 AND #4
#6 (africa[tw] OR africa’[tw] OR africa’s[tw] OR africa1[tw] OR africa2[tw] OR africaans[tw] OR africacollaborations[tw] OR africae[tw] OR
africaeaustralis[tw] OR africahiv[tw] OR africaid[tw] OR africaid’s[tw] OR africain[tw] OR africaine[tw] OR africaine’s[tw] OR africaines[tw]
OR africains[tw] OR africal[tw] OR africam[tw] OR africamum[tw] OR african[tw] OR african’[tw] OR african”[tw] OR african’s[tw]
OR african1[tw] OR african2[tw] OR africana[tw] OR africanae[tw] OR africanalleles[tw] OR africanamerican[tw] OR africanan[tw]
OR africanane[tw] OR africananes[tw] OR africanasian[tw] OR africanastrongylus[tw] OR africancalotropis[tw] OR africander[tw]
OR africanders[tw] OR africane[tw] OR africanendemic[tw] OR africanene[tw] OR africanenes[tw] OR africanensis[tw] OR
africanenvironment[tw] OR africaner[tw] OR africanes[tw] OR africani[tw] OR africanised[tw] OR africanism[tw] OR africanist[tw] OR
africanists[tw] OR africanity[tw] OR africanium[tw] OR africanizada[tw] OR africanization[tw] OR africanization’[tw] OR africanize[tw]
OR africanized[tw] OR africanized’[tw] OR africanizing[tw] OR africanjournal[tw] OR africannum[tw] OR africano[tw] OR
africanoides[tw] OR africanol[tw] OR africanos[tw] OR africanoside[tw] OR africanpatients[tw] OR africanpiper[tw] OR africans[tw]
OR africans’[tw] OR africanton[tw] OR africantrinervitermes[tw] OR africantriol[tw] OR africanum[tw] OR africanum’[tw] OR
africanumsp[tw] OR africanumt[tw] OR africanus[tw] OR africanus’[tw] OR africanusgen[tw] OR africanz[tw] OR africare[tw] OR
africarice[tw] OR africas[tw] OR africasia[tw] OR africative[tw]) OR Algeria[tw] OR Angola[tw] OR Benin[tw] OR Botswana[tw] OR
Burundi[tw] OR Cameroon[tw] OR Chad[tw] OR Comoros[tw] OR Congo[tw] OR Djibouti[tw] OR Egypt[tw] OR Eritrea[tw] OR
Ethiopia[tw] OR Gabon[tw] OR Gambia[tw] OR Ghana[tw] OR Guinea[tw] OR Jamahiriya[tw] OR Jamahiriya[tw] OR Kenya[tw] OR
Lesotho[tw] OR Liberia[tw] OR Libya[tw] OR Libya[tw] OR Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR Mauritania[tw] OR
Mauritius[tw] OR Mayotte[tw] OR Morocco[tw] OR Mozambique[tw] OR Mozambique[tw] OR Namibia[tw] OR Niger[tw] OR
Nigeria[tw] OR Principe[tw] OR Reunion[tw] OR Rwanda[tw] OR Senegal[tw] OR Seychelles[tw] OR Somalia[tw] OR Sudan[tw] OR
Swaziland[tw] OR Tanzania[tw] OR Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR Zaire[tw] OR Zambia[tw] OR Zimbabwe[tw]
#7 #5 AND #6
#8 2005/01/01[PDAT] : “2015/05/31”[PDAT]
#9 #7 AND #8
#10 AND “humans”[MeSH Terms]
#11 #9 AND #10
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Appendix 2
Table 3 Data collection form
Review title Epidemiology of hepatitis A virus in Africa among
persons aged 1–10 years: a systematic review protocol
Study ID Surname of first author and year article was published
e.g., John 2010
1. General information
Date form completed (dd/mm/yyyy)
Name of person extracting data
Full reference of article
Study author contact details





Study characteristics Eligibility criteria Yes/no Location in text
Period Between 2005 and May 2015
Setting African population
Participants Above 1 up to 10 years
Condition Positive anti-HAV antibodies






Do not proceed if study excluded from review
3. Participants
Description Location in text
Country
Study setting e.g., urban, rural, hospital based
Inclusion criteria (in the study)
Exclusion criteria (in the study)
Informed consent
Total population at start of study





Description Location in text
Aim of study
Study design
Unit of allocation (individuals, cluster, groups)
Start date
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Table 3 Data collection form (Continued)
End date
Total study duration
Type of diagnostic test
Ethical approval obtained for study
Notes:
5. Risk of bias assessment
Items Quality score Total score
External validity
1. Was the study’s target population a close representation of the
national population in relation to relevant variables
(1 point)
2. Was the sampling frame a true or close representation of the
target population?
(1 point)
3. Was some form of random selection used to select the sample,
OR was a census undertaken?
(1 point)
4. Was the likelihood of non-response bias minimal? (1 point)
Total (4 points)
Internal validity
1. Were data collected directly from the participants (as opposed to a proxy)? (1 point)
2. Was an acceptable case definition used in the study? (1 point)
3. Was the study instrument that measured the parameter of interest shown to
have validity and reliability?
(1 point)
4. Was the same mode of data collection used for all participants? (1 point)
5. Was the length of the shortest prevalence period for the parameter
of interest appropriate?
(1 point)






Outcomes Description as in article Location in text
Case definition
Unit of measurement
Number of cases (prevalence)
Total number of cases/total pop # of cases Total
pop
Number of new cases (incidence)





Key conclusions of study
References to other relevant studies
Correspondence required for further information
Other comments
Notes:
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